2. Search Result
Search Result
Results for "

human OGA

" in MedChemExpress (MCE) Product Catalog:

5

Inhibitors & Agonists

1

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-12588
    Thiamet G
    45+ Cited Publications

    		 OGA Autophagy Cancer
    Thiamet G is a potent and selective inhibitor of O-GlcNAcase (OGA), which acts to remove O-GlcNAc from modified proteins, with Ki of 20 nM for human OGA.
    Thiamet G
  • HY-149552
    Ac4-5SGlcNAc

    		OGT Cancer
    Ac4-5SGlcNAc is an O-GlcNAc transferase (OGT) inhibitor. Ac4-5SGlcNAc converts intracellularly to UDP-5SGlcNAc, which competes with native UDP-GlcNAc (HY-148596) to block OGT catalytic activity, reduces cellular UDP-GlcNAc pools, and limits global protein O-GlcNAcylation. Ac4-5SGlcNAc reduces OGA levels via feedback, alters lectin signal intensities and glycan-related band masses. Ac4-5SGlcNAc can be used for the research of breast cancer .
    Ac4-5SGlcNAc
  • HY-RS09757
    OGA Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    OGA Human Pre-designed siRNA Set A contains three designed siRNAs for OGA gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    OGA Human Pre-designed siRNA Set A
    OGA Human Pre-designed siRNA Set A
  • HY-E71360
    O-GlcNAcase, Clostridium perfringens

    		Glycosidase Others
    O-GlcNAcase, Clostridium perfringens is a glycosidase derived from Clostridium perfringens, which functions in bacterial nutrient metabolism, host interaction and virulence regulation. O-GlcNAcase is a core enzyme in the cellular signal regulatory network and serves as a key target for various major and chronic diseases. O-GlcNAcase, Clostridium perfringens can be used for basic research and drug development of O-GlcNAcase due to its high conservation in catalytic mechanism and structure with human-derived enzymes .
    O-GlcNAcase, Clostridium perfringens
  • HY-183557
    O-GlcNAcase-IN-6

    		OGA Neurological Disease
    O-GlcNAcase-IN-6 is an orally active, blood-brain barrier-permeable O-GlcNAcase (OGA) inhibitor with an IC50 of 5.4 nM. O-GlcNAcase-IN-6 inhibits OGA activity, thereby increasing the level of O-GlcNAc glycosylation in brain tissues. O-GlcNAcase-IN-6 can be used for the research of Alzheimer's disease .
    O-GlcNAcase-IN-6

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: